Memantine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/963765/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/963765/Cv/1'> | ||
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [https://en.wikipedia.org/wiki/Memantine]. | ||
<scene name='96/963765/Overall/1'>Memantine-bound GluN1a-GluN2B NMDA receptors</scene> ([[7sad]]); GluN1a subunits are in cyan, GluN2B subunits are in green, and memantine is in magenta. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||